GSA Capital Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

GSA Capital Partners’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-44,849	Closed	-$50K	–	2061
2022 Q4	$50K	Sell	44,849 -52,468	-54%	-$74.7K	0.01%	1359
2022 Q3	$228K	Buy	+97,317	New	+$345K	0.03%	1127
2021 Q4	–	Sell	-96,900	Closed	-$720K	–	1925
2021 Q3	$720K	Buy	96,900 +44,277	+84%	+$274K	0.07%	484
2021 Q2	$358K	Buy	+52,623	New	+$437K	0.04%	830
2021 Q1	–	Sell	-30,696	Closed	-$215K	–	1608
2020 Q4	$215K	Buy	+30,696	New	+$239K	0.04%	942
2020 Q2	–	Sell	-48,169	Closed	-$229K	–	1246
2020 Q1	$229K	Buy	+48,169	New	+$277K	0.06%	670
2019 Q4	–	Sell	-41,912	Closed	-$140K	–	1820
2019 Q3	$140K	Buy	41,912 +29,625	+241%	+$119K	0.02%	1236
2019 Q2	$61K	Sell	12,287 -26,315	-68%	-$140K	0.01%	1375
2019 Q1	$239K	Sell	38,602 -93,498	-71%	-$452K	0.02%	1132
2018 Q4	$445K	Buy	132,100 +28,000	+27%	+$131K	0.05%	619
2018 Q3	$677K	Buy	+104,100	New	+$774K	0.04%	924

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

GSA Capital Partners's JNCE Position: Q1 2023 in Review

GSA Capital Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 44,849 shares — an estimated $50K sold.

GSA Capital Partners first reported a position in JNCE in Q3 2018 and held it in 11 quarters. The position peaked at $720K in Q3 2021. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

GSA Capital Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
GSA Capital Partners sold 44,849 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $50K.
GSA Capital Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 11 quarters.
GSA Capital Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $720K in Q3 2021.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on GSA Capital Partners's 13F filing for Q1 2023, filed 12 May 2023.